Mirum Pharmaceuticals, Inc.
MIRM
Rang in aandelen
#3242
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Aandeelprijs
$83.62
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$5.43B
Verandering (1 dag)
-1.71%
Verandering (1 jaar)
20.14%
Land
US
Handel Mirum Pharmaceuticals, Inc. (MIRM)
Categorie
Healthcare
Koersgeschiedenis voor Mirum Pharmaceuticals, Inc. (MIRM)
Hoogste slotkoers: $82.31 op 2026-10-01
Laagste slotkoers: $13.66 op 2019-07-01
Laagste slotkoers: $13.66 op 2019-07-01
Koersgeschiedenis van Mirum Pharmaceuticals, Inc. van 2019 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 28.91% |
| 2025 | 68.24% |
| 2024 | 35.06% |
| 2023 | 73.09% |
| 2022 | 24.19% |
| 2021 | -29.47% |
| 2020 | 29.71% |
| 2019 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.70 | 7.84% |
CH
|
